Literature DB >> 6616446

Metastatic behavior of an adriamycin-resistant murine tumor.

R Giavazzi, L Miller, I R Hart.   

Abstract

The metastatic behavior of a murine fibrosarcoma (UV-2237M-ADMR) resistant to Adriamycin (ADM) (doxorubicin) was investigated. Subclones isolated from the UV-2237M-ADMR line, which originated from a single colony, generally displayed a similar degree of resistance to ADM (eight out of nine clones did not differ from this UV-2237M-ADMR line). In contrast, they differed significantly in their capacity to form lung colonies after i.v. injection (six of nine clones differed significantly from the UV-2237M-ADMR line, p less than or equal to 0.005, Mann-Whitney U test). The UV-2237M-ADMR cell line maintained resistance to ADM even after 17 weeks of growth in syngeneic mice, although a gradual decrease in resistance was observed over this time. Spontaneous metastases from the UV-2237M-ADMR tumor commonly retained resistance to ADM. Of 18 cell lines, each established from an individual lung nodule, 16 showed plating efficiencies in the presence of ADM comparable to that of the primary UV-2237M-ADMR tumor. The remaining two lines had partially reverted to the sensitive state. The i.v. administration of ADM significantly reduced the lung tumor burden of mice with ADM-sensitive UV-2237M tumors but failed to affect the lung tumor burden of mice with UV-2237M-ADMR tumors. The UV-2237M-ADMR tumor line, exhibiting as it does both drug-resistant and metastatic behavior, provides a useful model system with which to investigate the metastatic process and the development of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Can cancer chemotherapy enhance the malignant behaviour of tumours?

Authors:  T J McMillan; I R Hart
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Growth of metastases of the mouse adenocarcinoma EO 771: an allometric relationship between growth of the primary tumors and their metastases.

Authors:  I D Bassukas; B Maurer-Schultze
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

3.  Heterogeneity of isozyme expression in tumor cells does not correlate with metastatic potential.

Authors:  S L Aukerman; M J Siciliano; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1986 Jul-Sep       Impact factor: 5.150

4.  The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype.

Authors:  J J Killion; R Radinsky; Z Dong; R Fishbeck; P Whitworth; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

5.  Expression of mdr1 gene in human breast primary tumors and metastases.

Authors:  E Hennequin; C Delvincourt; C Pourny; J C Jardillier
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 6.  Modulation of tumor cell response to chemotherapy by the organ environment.

Authors:  I J Fidler; C Wilmanns; A Staroselsky; R Radinsky; Z Dong; D Fan
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

7.  A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycin.

Authors:  C A O'Brian; N E Ward; R M Liskamp; D B de Bont; L E Earnest; J H van Boom; D Fan
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

8.  SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Authors:  Shannon P Fortin Ensign; Alison Roos; Ian T Mathews; Harshil D Dhruv; Serdar Tuncali; Jann N Sarkaria; Marc H Symons; Joseph C Loftus; Michael E Berens; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2016-01-13       Impact factor: 5.852

9.  A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.

Authors:  S A Glynn; P Gammell; M Heenan; R O'Connor; Y Liang; J Keenan; M Clynes
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.